Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

医学 彭布罗利珠单抗 内科学 安慰剂 肿瘤科 多西紫杉醇 中期分析 化疗 队列 癌症 外科 临床试验 免疫疗法 病理 替代医学
作者
Kohei Shitara,Sun Young Rha,Lucjan Stanislaw Wyrwicz,Takashi Oshima,Nina A. Karaseva,Mikhail Osipov,Hisateru Yasui,Hiroshi Yabusaki,Sergey G. Afanasyev,Young Kyu Park,Salah-Eddin Al-Batran,Takaki Yoshikawa,Patricio Eduardo Yanez,Maria Di Bartolomeo,Sara Lonardi,Josep M. Tabernero,Eric Van Cutsem,Yelena Yuriy Janjigian,Do‐Youn Oh,Jianming Xu
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:25 (2): 212-224 被引量:441
标识
DOI:10.1016/s1470-2045(23)00541-7
摘要

Background The benefit of combination neoadjuvant and adjuvant chemotherapy and immune checkpoint inhibition in patients with locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma is unknown. We assess the antitumor activity of neoadjuvant and adjuvant pembrolizumab plus chemotherapy in patients with locally advanced resectable gastric or gastro-oesophageal adenocarcinoma. Methods The KEYNOTE-585 study is a multicentre, randomised, placebo-controlled, double-blind, phase 3 study done at 143 medical centres in 24 countries. Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma, and an Eastern Cooperative Oncology Group performance status 0–1. Patients were randomly assigned (1:1) by an interactive voice response system and integrated web response system to neoadjuvant pembrolizumab 200 mg intravenously or placebo (saline) plus cisplatin-based doublet chemotherapy (main cohort) every 3 weeks for 3 cycles, followed by surgery, adjuvant pembrolizumab or placebo plus chemotherapy for 3 cycles, then adjuvant pembrolizumab or placebo for 11 cycles. A small cohort was also randomly assigned (1:1) to pembrolizumab or placebo plus fluorouracil, docetaxel, and oxaliplatin (FLOT)-based chemotherapy (FLOT cohort) every 2 weeks for four cycles, followed by surgery, adjuvant pembrolizumab, or placebo plus FLOT for four cycles, then adjuvant pembrolizumab or placebo for 11 cycles. Patients were stratified by geographic region, tumour stage, and chemotherapy backbone. Primary endpoints were pathological complete response (reviewed centrally), event-free survival (reviewed by the investigator), and overall survival in the intention-to-treat population, and safety assessed in all patients who received at least one dose of study treatment. The study is registered at ClinicalTrials.gov, NCT03221426, and is closed to accrual. Findings Between Oct 9, 2017, and Jan 25, 2021, of 1254 patients screened, 804 were randomly assigned to the main cohort, of whom 402 were assigned to the pembrolizumab plus cisplatin-based chemotherapy group and 402 to the placebo plus cisplatin-based chemotherapy group, and 203 to the FLOT cohort, of whom 100 were assigned to the pembrolizumab plus FLOT group and 103 to placebo plus FLOT group. In the main cohort of 804 participants, 575 (72%) were male and 229 (28%) were female. In the main cohort, after median follow-up of 47·7 months (IQR 38·0–54·8), pembrolizumab was superior to placebo for pathological complete response (52 [12·9%; 95% CI 9·8–16·6] of 402 vs eight [2·0%; 0·9–3·9] of 402; difference 10·9%, 95% CI 7·5 to 14·8; p<0·00001). Median event-free survival was longer with pembrolizumab versus placebo (44·4 months, 95% CI 33·0 to not reached vs 25·3 months, 20·6 to 33·9; hazard ratio [HR] 0·81, 95% CI 0·67 to 0·99; p=0·0198) but did not meet the threshold for statistical significance (p=0·0178). Median overall survival was 60·7 months (95% CI 51·5 to not reached) in the pembrolizumab group versus 58·0 months (41·5 to not reached) in the placebo group (HR 0·90, 95% CI 0·73 to 1·12; p=0·174). Grade 3 or worse adverse events of any cause occurred in 312 (78%) of 399 patients in the pembrolizumab group and 297 (74%) of 400 patients in the placebo group; the most common were nausea (240 [60%] vs 247 [62%]), anaemia (168 [42%] vs 158 [40%]), and decreased appetite (163 [41%] vs 172 [43%]). Treatment-related serious adverse events were reported in 102 (26%) and 97 (24%) patients. Treatment-related adverse events that led to death occurred in four (1%) patients in the pembrolizumab group (interstitial ischaemia, pneumonia, decreased appetite, and acute kidney injury [n=1 each]) and two (<1%) patients in the placebo group (neutropenic sepsis and neutropenic colitis [n=1 each]). Interpretation Although neoadjuvant and adjuvant pembrolizumab versus placebo improved the pathological complete response, it did not translate to significant improvement in event-free survival in patients with untreated, locally advanced resectable gastric or gastro-oesophageal cancer. Funding Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
etheral完成签到 ,获得积分10
1秒前
鱼梓发布了新的文献求助10
1秒前
1秒前
2秒前
情怀的应助被Jacky采纳,获得10
2秒前
小燕尾条发布了新的文献求助10
2秒前
hjhhjh完成签到,获得积分10
3秒前
3秒前
3秒前
4秒前
风有约完成签到 ,获得积分10
5秒前
6秒前
踏实凡桃发布了新的文献求助10
6秒前
共享精神的应助被开心德地采纳,获得10
7秒前
打打的应助被整点可乐采纳,获得10
7秒前
7秒前
7秒前
8秒前
9秒前
CipherSage的应助被ke采纳,获得10
9秒前
19完成签到,获得积分10
10秒前
interguy发布了新的文献求助10
10秒前
12秒前
强强完成签到,获得积分10
13秒前
四十发布了新的文献求助10
13秒前
14秒前
15秒前
15秒前
16秒前
踏实凡桃完成签到,获得积分20
16秒前
贾贡献的应助被Dream采纳,获得10
19秒前
19秒前
19秒前
小马甲的应助被开心德地采纳,获得10
20秒前
洁净宝莹发布了新的文献求助10
20秒前
顺利的西瓜完成签到,获得积分10
21秒前
21秒前
求助文献发布了新的文献求助10
21秒前
yanczc发布了新的文献求助10
21秒前
BeBrave1028完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188654
求助须知:如何正确求助?哪些是违规求助? 9576372
关于积分的说明 21847161
捐赠科研通 7786741
什么是DOI,文献DOI怎么找? 3435402
关于科研通互助平台的介绍 2559632
邀请新用户注册赠送积分活动 2482360